Regimen Reference Order

GYNE – bevacizumab + pegylated liposomal doxorubicin

ARIA: GYNE - [bev + doxorubicin (peg-liposomal]

Planned Course: Every 28 days until disease progression or unacceptable toxicity
Indication for Use: Ovarian Cancer Platinum-Resistant

CVAD: At Provider's Discretion

Proceed with treatment if:
Cycle 1
Day 1 only
- ***ANC equal to or greater than 1.5 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L***

Cycle 2 and Onwards
Day 1 only
- ***ANC equal to or greater than 1.2 x 10^9/L AND Platelets equal to or greater than 75 x 10^9/L***
  - ❖ **Contact Physician if parameters not met**

***Note:** Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients*

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GYNE – bevacizumab + pegylated liposomal doxorubicin

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Day 1		
bevacizumab (brand name specific)	10 mg/kg	IV in normal saline 100 mL over 20 minutes **Alert:* *Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order*
Establish primary solution 500 mL of: D5W (pegylated liposomal doxorubicin incompatible with normal saline)		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy

doxorubicin, peg-liposomal (pegylated liposomal doxorubicin)	40 mg/m^2	**Dose less than 90 mg:** IV in D5W 250 mL	**First Dose:** Over 90 minutes *(Maximum rate 1 mg/minute)*
			Subsequent Doses (if no reaction): Over 1 hour
		Dose greater than or equal to 90 mg: IV in D5W 500 mL	**First Dose:** Over 2 hours *(Maximum rate 1 mg/minute)*
			Subsequent Doses (if no reaction): Over 1 hour
Day 15			
Establish primary solution 500 mL of: normal saline			
bevacizumab (brand name specific)	10 mg/kg	IV in normal saline 100 mL over 20 minutes **Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order*	
All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information			

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

Hepatitis B serology

- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

Days 1

- CBC, serum creatinine, liver enzymes, urine protein and blood pressure as per Physician Orders
  - Urinalysis for protein: Where urinalysis is not possible, use dipstick. If lab urinalysis for protein is greater than or equal to 1 g/L or dipstick proteinuria shows 2+ or 3+, notify prescriber
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- No observation period is required after bevacizumab or pegylated liposomal doxorubicin. Patient can be discharged from treatment room if stable whether they had a reaction or not

Day 15

- No blood work required on Day 15
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- No observation period is required after bevacizumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- bevacizumab can cause increased risk of hypertension, post-operative bleeding, wound healing complications and thromboembolic events
- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy ***Hepatitis B Monitoring for Oncology and Hematology Patients*** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- bevacizumab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after bevacizumab. **Ensure prescription label matches the brand name on prescribed order**